WO2006013015A3 - Diagnostics et therapeutique pour maladies liees a la marapsine (mpn) - Google Patents
Diagnostics et therapeutique pour maladies liees a la marapsine (mpn) Download PDFInfo
- Publication number
- WO2006013015A3 WO2006013015A3 PCT/EP2005/007954 EP2005007954W WO2006013015A3 WO 2006013015 A3 WO2006013015 A3 WO 2006013015A3 EP 2005007954 W EP2005007954 W EP 2005007954W WO 2006013015 A3 WO2006013015 A3 WO 2006013015A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- mpn
- marapsin
- therapeutics
- diagnostics
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 102100040107 Serine protease 27 Human genes 0.000 title abstract 2
- 101710197422 Serine protease 27 Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 101000610616 Homo sapiens Serine protease 27 Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000045925 human PRSS27 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne la marapsine humaine (MPN) associée aux maladies cardio-vasculaires, aux infections, aux maladies gastroentérologiques, au cancer, aux maladies hématologiques, aux maladies respiratoires, aux inflammations, aux maladies du métabolisme, aux maladies du squelette et des muscles, aux maladies neurologiques et aux maladies urologiques. Cette invention a aussi pour objet des dosages destinés à l'identification de composés utilisés dans le traitement ou la prévention de maladies cardio-vasculaires, d'infections, de maladies gastroentérologiques, de cancer, de maladies hématologiques, de maladies respiratoires, d'inflammations, de maladies du métabolisme, de maladies du squelette et des muscles, de maladies neurologiques et de maladies urologiques. Ladite invention a également trait à des composés qui se lient et/ou activent ou inhibent l'activité de MPN, ainsi que des compositions pharmaceutiques contenant de tels composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04018444.2 | 2004-08-04 | ||
| EP04018444 | 2004-08-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006013015A2 WO2006013015A2 (fr) | 2006-02-09 |
| WO2006013015A3 true WO2006013015A3 (fr) | 2006-03-30 |
Family
ID=35406043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/007954 WO2006013015A2 (fr) | 2004-08-04 | 2005-07-21 | Diagnostics et therapeutique pour maladies liees a la marapsine (mpn) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006013015A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275547B1 (fr) | 2004-12-13 | 2014-03-05 | Alethia Biotherapeutics Inc. | Polynucléotides et séquences de polypeptide impliquées dans le procédé de remodelage des os |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0890646A2 (fr) * | 1997-06-10 | 1999-01-13 | Smithkline Beecham Plc | HE2NW40 Sérine protéase |
| US6165771A (en) * | 1997-06-10 | 2000-12-26 | Smithkline Beecham, P.L.C. | Compounds |
| WO2001016293A2 (fr) * | 1999-08-31 | 2001-03-08 | Ortho-Mcneil Pharmaceutical, Inc. | Adn codant la serine protease t humaine |
| GB2376234A (en) * | 2001-03-14 | 2002-12-11 | Glaxo Group Ltd | Trypsin-like serine protease |
-
2005
- 2005-07-21 WO PCT/EP2005/007954 patent/WO2006013015A2/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0890646A2 (fr) * | 1997-06-10 | 1999-01-13 | Smithkline Beecham Plc | HE2NW40 Sérine protéase |
| US6165771A (en) * | 1997-06-10 | 2000-12-26 | Smithkline Beecham, P.L.C. | Compounds |
| WO2001016293A2 (fr) * | 1999-08-31 | 2001-03-08 | Ortho-Mcneil Pharmaceutical, Inc. | Adn codant la serine protease t humaine |
| US6458564B1 (en) * | 1999-08-31 | 2002-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | DNA encoding the human serine protease T |
| GB2376234A (en) * | 2001-03-14 | 2002-12-11 | Glaxo Group Ltd | Trypsin-like serine protease |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE EMBL [online] 21 December 2002 (2002-12-21), "Sequence 1 from patent US 6458564.", XP002356764, retrieved from EBI accession no. EM_PRO:AR234331 Database accession no. AR234331 * |
| DATABASE Geneseq [online] 16 May 2003 (2003-05-16), "Human serine protease, HIPHUM 31.", XP002356760, retrieved from EBI accession no. GSN:ABG73394 Database accession no. ABG73394 * |
| DATABASE Geneseq [online] 29 May 2001 (2001-05-29), "Human protease T cDNA.", XP002356761, retrieved from EBI accession no. GSN:AAF76994 Database accession no. AAF76994 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006013015A2 (fr) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006027147A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr) | |
| WO2005093092A3 (fr) | Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44) | |
| WO2005106012A3 (fr) | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1) | |
| WO2006010498A3 (fr) | Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2) | |
| WO2006010517A3 (fr) | Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap) | |
| WO2005106491A3 (fr) | Diagnostic et traitement therapeutique de maladies associees a la kinase 1 regulee par serum/glucocorticoide (sgk1) | |
| WO2006010514A3 (fr) | Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite | |
| WO2005113786A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1) | |
| WO2006013015A3 (fr) | Diagnostics et therapeutique pour maladies liees a la marapsine (mpn) | |
| WO2006021343A3 (fr) | Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a) | |
| WO2005076007A3 (fr) | Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12) | |
| WO2005093091A3 (fr) | Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26) | |
| WO2005106486A3 (fr) | Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3) | |
| WO2006013012A3 (fr) | Diagnostics et therapeutique pour maladies liees a la napsine 1 (nap1) | |
| WO2006010497A3 (fr) | Diagnostics et therapeutiques pour des maladies associees a choline kinase (chk) | |
| WO2006013014A3 (fr) | Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal) | |
| WO2006005470A3 (fr) | Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge) | |
| WO2005101011A3 (fr) | Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra) | |
| WO2005100997A3 (fr) | Moyens diagnostiques et therapeutiques pour maladies associees au recepteur de tachykinine 3 (tacr3) | |
| WO2005026719A3 (fr) | Diagnostic et traitement de maladies associees au transporteur de cations organiques slc22a3 (slc22a3) | |
| WO2006013013A3 (fr) | Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb) | |
| WO2005101009A3 (fr) | Outils diagnostiques et therapeutiques pour maladies associees au recepteur 2 de tachykinine (tacr2) | |
| WO2005114210A8 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3) | |
| WO2006010489A3 (fr) | Diagnostic et traitement de maladies associees a la proteine chkl | |
| WO2006010495A3 (fr) | Moyens de diagnostic et de traitement pour des maladies associees a la carboxypeptidase a3 (cpa3) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |